Navigation Links
CRF announces late breaking trials and first report investigations to be presented at TCT 2010
Date:8/5/2010

NEW YORK, NY August 5, 2010 The Cardiovascular Research Foundation has announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2010 scientific symposium. Findings from these clinical trials are expected to significantly impact interventional cardiology practices and patient care. TCT 2010 will take place September 21 25 in Washington, DC.

The studies selected will shed new light on the effectiveness of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent heart disease, one of the leading causes of death globally.

Late-breaking clinical trials and first report investigations will be highlighted during press conferences scheduled for Thursday, September 23, Friday, September 24, and Saturday, September 25.

THURSDAY, SEPTEMBER 23
Late Breaking Trials

  • PARTNER: A Prospective Randomized Trial of Transcatheter Aortic Valve Implantation Compared to Standard Therapy in Patients with Inoperable Aortic Stenosis
  • SPIRIT IV: Two-Year Results from a Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease
  • COMPARE: Two-Year Results from a Prospective Randomized Trial of Everolimus-Eluting Stents Compared to Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease

First Report Investigations

  • LANCELOT ACS: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Reversible PAR-1 Thrombin Receptor Antagonist in Patients with Acute Coronary Syndromes
  • LEVANT I: A Prospective Randomized Trial of a Paclitaxel-Eluting Balloon Compared to a Non-Drug-Eluting Balloon With and Without Stenting in Patients with Diseased Femoropopliteal Arteries
  • PERfECT STENT: A Prospective Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients Treated with Endothelial Progenitor Cell Capturing Stents for De Novo Coronary Artery Disease

FRIDAY, SEPTEMBER 24
Late Breaking Trials

  • ZILVER PTX: A Prospective Randomized Trial of a Paclitaxel-Eluting Stent Compared to Balloon Angioplasty with Provisional Bare Metal Stenting in Patients with Superficial Femoral Artery Disease
  • SORT OUT 4: A Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
  • ISAR-TEST-4: Two-Year Clinical and Angiographic Outcomes from a Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease

First Report Investigations

  • DES-BTK: A Prospective, Double-Blind, Randomized Trial of Polymer-Free Sirolimus-Eluting Stents Compared to Bare Metal Stents in Patients with Infrapopliteal Disease
  • TORPEDO: A Prospective Randomized Trial of Percutaneous Endovenous Intervention Compared to Anticoagulation Alone in Patients with Deep Venous Thrombosis
  • BLAST: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of a Monocyte-Depleting Agent After Bare Metal Stents in Patients with Coronary Artery Disease

SATURDAY, SEPTEMBER 25
Late Breaking Trials

  • ISAR-TEST-5: A Prospective Randomized Trial of Polymer-Free Sirolimus-/Probucol-Eluting Stents Compared to Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease
  • HORIZONS-AMI: Three-Year Follow-up from a Prospective Randomized Trial of Antithrombin Strategies and Drug-Eluting Stents in Patients with Acute Myocardial Infarction Undergoing Primary Angioplasty
  • CRISTAL: A Prospective Randomized Trial of Sirolimus-Eluting Stents Compared to Balloon Angioplasty for Restenosis of Drug-Eluting Coronary Stents

First Report Investigations

  • BIOFREEDOM: A Prospective Randomized Trial of Polymer-Free Biolimus A9-Eluting Stents and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease
  • AVIO: A Prospective Randomized Trial of Intravascular Ultrasound-Guided Compared to Angiography-Guided Stent Implantation in Complex Coronary Lesions
  • EXCELLENT: A Prospective Randomized Trial of Everolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. ASP announces 2010 T. Franklin Williams Scholars
2. Feng Shui Expert Practitioner and Analyst Angel de Para Announces Classical Feng Shui Practitioner Workshop in New York City.
3. Lifeloc supports workplace breath alcohol testing and announces new robust solution, the EV30T
4. QualEDIx Announces the Launch of the Nation's Only Managed Service Model for HIPAA 5010 and ICD-10 Testing
5. ASTRO announces 2010 Fellows class
6. NOSCAR announces first NOTES transoral and transvaginal gallbladder removals performed as part of US multicenter human trial
7. Bling My Sling LL Announces Website Launch - A fashionable arm sling manufacturer, announce the opening of their new website bling-my-sling.com
8. Health Literacy Innovations Announces 1st Annual Health Literacy Innovator Award — Anonymous Donor Offers Prize Money To Winners
9. IVR Technology Group Announces MobileMarketing123.com
10. RSLSteeper announces pricing for new bionic hand
11. SNMs Technologist Section announces award winners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... “Spiritual ... improve the connection with God. “Spiritual Vitamins: A Spiritual Energy Booster” is the ... Christian Faith Publishing, Mathai Yohannan’s new book engages the mind and spirit in ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... refined coffee house-caliber protein and espresso drink, announced its CLICK® Coffee Protein Drink ... , CLICK® Coffee Protein Drink Mix has become popular among health-conscious consumers who ...
(Date:1/24/2017)... ... January 23, 2017 , ... Texas Home Health, an ... two personal care service companies: Padre Home Health in Corpus Christi, Texas, and ... , Well regarded in their respective markets, these two agencies align with Texas ...
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern ... new domain address. Alpine Springs Rehabilitation & Recovery Center’s new website can be ... logo along with its redesigned and retooled website. The treatment center has also ...
(Date:1/23/2017)... ... January 23, 2017 , ... The iaedp ... for healthcare treatment providers who treat the full spectrum of eating disorder problems, ... The Presidents Council consists of the leading eating disorder treatments centers located throughout ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... The global peripheral I.V. catheter market accounted ... expected to grow at a CAGR of 6.0% during ... larger share in the global market between the two ... the hospital segment accounted for the highest share in ... peripheral I.V. catheter market is witnessing high growth rate, ...
(Date:1/23/2017)... Calif. , Jan. 23, 2017  HOPE ... exclusive rights to develop and commercialize nuc ... Therapeutics, a Korean pharmaceutical company. ... DNA aptamer against surface nucleolin found on many ... gemcitabine. Unlike ADCs (antibody drug conjugates) or SMDCs ...
(Date:1/23/2017)... Calif. , Jan. 23, 2017  Based ... market, Frost & Sullivan recognizes Ansell, a global ... Frost & Sullivan Company of the Year Award. ... approach, and a wide global footprint have placed ... the hand protection market. The Company,s established product ...
Breaking Medicine Technology: